The Diagnostic and Clinical Significance of Café-au-lait Macules

Pediatric Clinics of North America

Volumn 57, Issue 5, 2010, Pages 1131-1153

  Shah, Kara N ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Caf au lait; Neurofibromatosis; NF 1

Indexed keywords

ATM PROTEIN; MISMATCH REPAIR PROTEIN PMS2; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN TYROSINE PHOSPHATASE SHP 2; SCATTER FACTOR; STEM CELL FACTOR;

ALBRIGHT SYNDROME; BECKER NEVUS; CAFE AU LAIT SPOT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GENETIC DISORDER; HUMAN; HYPERPIGMENTATION; LEGUIS SYNDROME; LENTIGO; LEOPARD SYNDROME; LOW LEVEL LASER THERAPY; MASTOCYTOMA; MELANOCYTIC NEVUS; MELANOMA; MENINGIOMA; MOSAICISM; NEUROFIBROMATOSIS; NOONAN SYNDROME; PATHOGENESIS; PREVALENCE; REVIEW; RING CHROMOSOME; SKIN HEMANGIOMA; URTICARIA PIGMENTOSA; CAFE-AU-LAIT SPOTS; CHILD; CHILD WELFARE; COMPLICATION; INFANT; NEUROFIBROMATOSIS 1; NEVUS, PIGMENTED; NEWBORN; PATHOLOGY; RISK FACTOR; SKIN; SKIN ABNORMALITIES; SYNDROME;

CAFE-AU-LAIT SPOTS; CHILD; CHILD WELFARE; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERPIGMENTATION; INFANT; INFANT, NEWBORN; NEUROFIBROMATOSIS 1; NEVUS, PIGMENTED; RISK FACTORS; SKIN; SKIN ABNORMALITIES; SYNDROME;

EID: 77957263081     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.07.002     Document Type: Review

References (160)

1. Ortonne J.P., Brocard E., Floret D., et al. Ann Dermatol Venereol 1980, 107:313. [in French].
2. De Schepper S., Boucneau J., Vander Haeghen Y., et al. Café-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind?. Arch Dermatol Res 2006, 297:439.
3. Kaufmann D., Krone W., Hochsattel R., et al. A cell culture study on melanocytes from patients with neurofibromatosis-1. Arch Dermatol Res 1989, 281:510.
4. Alper J., Holmes L.B., Mihm M.C. Birthmarks with serious medical significance: nevocullular nevi, sebaceous nevi, and multiple café au lait spots. J Pediatr 1979, 95:696.
5. Alper J.C., Holmes L.B. The incidence and significance of birthmarks in a cohort of 4,641 newborns. Pediatr Dermatol 1983, 1:58.
6. Whitehouse D. Diagnostic value of the café-au-lait spot in children. Arch Dis Child 1966, 41:316.
7. Burwell R.G., James N.J., Johnston D.I. Café-au-lait spots in schoolchildren. Arch Dis Child 1982, 57:631.
8. McLean D.I., Gallagher R.P. " Sunburn" freckles, café-au-lait macules, and other pigmented lesions of schoolchildren: the Vancouver Mole Study. J Am Acad Dermatol 1995, 32:565.
9. Rivers J.K., MacLennan R., Kelly J.W., et al. The eastern Australian childhood nevus study: prevalence of atypical nevi, congenital nevus-like nevi, and other pigmented lesions. J Am Acad Dermatol 1995, 32:957.
10. Sigg C., Pelloni F., Schnyder U.W. Frequency of congenital nevi, nevi spili and café-au-lait spots and their relation to nevus count and skin complexion in 939 children. Dermatologica 1990, 180:118.
11. Riccardi V.M. Von Recklinghausen neurofibromatosis. N Engl J Med 1981, 305:1617.
12. Ducker P., Pfeiff B., Pullmann H. Z Hautkr 1990, 65:751. [in German].
13. Perkinson N.G. Melanoma arising in a café au lait spot of neurofibromatosis. Am J Surg 1957, 93:1018.
14. Korf B.R. Diagnostic outcome in children with multiple café au lait spots. Pediatrics 1992, 90:924.
15. Fois A., Calistri L., Balestri P., et al. Relationship between café-au-lait spots as the only symptom and peripheral neurofibromatosis (NF1): a follow-up study. Eur J Pediatr 1993, 152:500.
16. Nunley K.S., Gao F., Albers A.C., et al. Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol 2009, 145:883.
17. Crowe F.W., Schull W.J. Diagnostic importance of café-au-lait spot in neurofibromatosis. AMA Arch Intern Med 1953, 91:758.
18. Gutmann D.H., Aylsworth A., Carey J.C., et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51.
19. Stumpf D.A., Alksne J.F., Annegers J.F., et al. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988, 45:575.
20. Listernick R., Ferner R.E., Liu G.T., et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007, 61:189.
21. Listernick R., Louis D.N., Packer R.J., et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force. Ann Neurol 1997, 41:143.
22. DeBella K., Szudek J., Friedman J.M. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000, 105:608.
23. Boyd K.P., Korf B.R., Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009, 61:1.
24. Listernick R., Charrow J. Neurofibromatosis-1 in childhood. Adv Dermatol 2004, 20:75.
25. Williams V.C., Lucas J., Babcock M.A., et al. Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124.
26. Obringer A.C., Meadows A.T., Zackai E.H. The diagnosis of neurofibromatosis-1 in the child under the age of 6 years. Am J Dis Child 1989, 143:717.
27. Rosser T., Packer R.J. Neurofibromas in children with neurofibromatosis 1. J Child Neurol 2002, 17:585.
28. Tonsgard J.H., Kwak S.M., Short M.P., et al. CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology 1998, 50:1755.
29. Evans D.G., Baser M.E., McGaughran J., et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002, 39:311.
30. Gutmann D.H., Gurney J.G., Shannon K.M. Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia. Arch Dermatol 1996, 132:1390.
31. Zvulunov A., Barak Y., Metzker A. Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis. Arch Dermatol 1995, 131:904.
32. Ferner R.E. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007, 6:340.
33. Rosser T.L., Vezina G., Packer R.J. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005, 64:553.
34. Bader J.L., Miller R.W. Neurofibromatosis and childhood leukemia. J Pediatr 1978, 92:925.
35. Matsui I., Tanimura M., Kobayashi N., et al. Neurofibromatosis type 1 and childhood cancer. Cancer 1993, 72:2746.
36. McKeen E.A., Bodurtha J., Meadows A.T., et al. Rhabdomyosarcoma complicating multiple neurofibromatosis. J Pediatr 1978, 93:992.
37. Miettinen M., Fetsch J.F., Sobin L.H., et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006, 30:90.
38. Stiller C.A., Chessells J.M., Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994, 70:969.
39. Walther M.M., Herring J., Enquist E., et al. von Recklinghausen's disease and pheochromocytomas. J Urol 1999, 162:1582.
40. Rosser T., Packer R.J. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 2002, 17:630.
41. Ferner R.E., Hughes R.A., Hall S.M., et al. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet 2004, 41:837.
42. Dulai S., Briody J., Schindeler A., et al. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 2007, 27:472.
43. Lammert M., Friedman J.M., Roth H.J., et al. Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet 2006, 43:810.
44. Lammert M., Kappler M., Mautner V.F., et al. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 2005, 16:1161.
45. Huson S.M., Hughes R.A. The neurofibromatoses: a pathogenetic and clinical overview 1994, Chapman & Hall Medical, London, New York. 1st edition.
46. Carey J.C., Laub J.M., Hall B.D. Penetrance and variability in neurofibromatosis: a genetic study of 60 families. Birth Defects Orig Artic Ser 1979, 15:271.
47. Huson S.M., Compston D.A., Clark P., et al. A genetic study of von Recklinghausen neurofibromatosis in South East Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989, 26:704.
48. Cawthon R.M., Weiss R., Xu G.F., et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990, 62:193.
49. Viskochil D., Buchberg A.M., Xu G., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187.
50. Wallace M.R., Marchuk D.A., Andersen L.B., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181.
51. Aoki Y., Niihori T., Narumi Y., et al. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 2008, 29:992.
52. Jadayel D., Fain P., Upadhyaya M., et al. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature 1990, 343:558.
53. Stephens K., Kayes L., Riccardi V.M., et al. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 1992, 88:279.
54. Rasmussen S.A., Friedman J.M. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151:33.
55. Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 2002, 17:562.
56. De Raedt T., Brems H., Wolkenstein P., et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003, 72:1288.
57. Leppig K.A., Kaplan P., Viskochil D., et al. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 1997, 73:197.
58. Leppig K.A., Viskochil D., Neil S., et al. The detection of contiguous gene deletions at the neurofibromatosis 1 locus with fluorescence in situ hybridization. Cytogenet Cell Genet 1996, 72:95.
59. Mensink K.A., Ketterling R.P., Flynn H.C., et al. Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature. J Med Genet 2006, 43:e8.
60. Messiaen L.M., Callens T., Mortier G., et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000, 15:541.
61. Riccardi V.M., Lewis R.A. Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants. Am J Hum Genet 1988, 42:284.
62. De Schepper S., Maertens O., Callens T., et al. Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol 2008, 128:1050.
63. Maertens O., Brems H., Vandesompele J., et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat 2006, 27:1030.
64. Listernick R., Mancini A.J., Charrow J. Segmental neurofibromatosis in childhood. Am J Med Genet A 2003, 121A:132.
65. Miller R.M., Sparkes R.S. Segmental neurofibromatosis. Arch Dermatol 1977, 113:837.
66. Moss C., Green S.H. What is segmental neurofibromatosis?. Br J Dermatol 1994, 130:106.
67. Redlick F.P., Shaw J.C. Segmental neurofibromatosis follows Blaschko's lines or dermatomes depending on the cell line affected: case report and literature review. J Cutan Med Surg 2004, 8:353.
68. Tinschert S., Naumann I., Stegmann E., et al. Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000, 8:455.
69. Cecchi R., Giomi A., Tuci F., et al. Bilateral segmental neurofibromatosis. Dermatology 1992, 185:59.
70. Gonzalez G., Russi M.E., Lodeiros A. Bilateral segmental neurofibromatosis: a case report and review. Pediatr Neurol 2007, 36:51.
71. Kajimoto A., Oiso N., Fukai K., et al. Bilateral segmental neurofibromatosis with gastric carcinoma. Clin Exp Dermatol 2007, 32:43.
72. Krishnan R.S., Angel T.A., Orengo I.F., et al. Bilateral segmental neurofibromatosis: a case report and review. Int J Dermatol 2001, 40:409.
73. Nagaoka Y., Asahina A., Yano S., et al. Bilateral segmental neurofibromatosis. Acta Derm Venereol 2002, 82:219.
74. Takiguchi P.S., Ratz J.L. Bilateral dermatomal neurofibromatosis. J Am Acad Dermatol 1984, 10:451.
75. Ars E., Kruyer H., Gaona A., et al. A clinical variant of neurofibromatosis type 1: familial spinal neurofibromatosis with a frameshift mutation in the NF1 gene. Am J Hum Genet 1998, 62:834.
76. Messiaen L., Riccardi V., Peltonen J., et al. Independent NF1 mutations in two large families with spinal neurofibromatosis. J Med Genet 2003, 40:122.
77. Baralle D., Mattocks C., Kalidas K., et al. Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS). Am J Med Genet A 2003, 119A:1.
78. Colley A., Donnai D., Evans D.G. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 1996, 49:59.
79. De Luca A., Bottillo I., Sarkozy A., et al. NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 2005, 77:1092.
80. Huffmeier U., Zenker M., Hoyer J., et al. A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene. Am J Med Genet A 2006, 140:2749.
81. Denayer E., de Ravel T., Legius E. Clinical and molecular aspects of RAS related disorders. J Med Genet 2008, 45:695.
82. Denayer E., Legius E. What's new in the neuro-cardio-facial-cutaneous syndromes?. Eur J Pediatr 2007, 166:1091.
83. Quezada E., Gripp K.W. Costello syndrome and related disorders. Curr Opin Pediatr 2007, 19:636.
84. Abeliovich D., Gelman-Kohan Z., Silverstein S., et al. Familial café au lait spots: a variant of neurofibromatosis type 1. J Med Genet 1995, 32:985.
85. Brunner H.G., Hulsebos T., Steijlen P.M., et al. Exclusion of the neurofibromatosis 1 locus in a family with inherited café-au-lait spots. Am J Med Genet 1993, 46:472.
86. Charrow J., Listernick R., Ward K. Autosomal dominant multiple café-au-lait spots and neurofibromatosis-1: evidence of non-linkage. Am J Med Genet 1993, 45:606.
87. Riccardi V.M. Pathophysiology of neurofibromatosis. IV. Dermatologic insights into heterogeneity and pathogenesis. J Am Acad Dermatol 1980, 3:157.
88. Brems H., Chmara M., Sahbatou M., et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007, 39:1120.
89. Wakioka T., Sasaki A., Kato R., et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature 2001, 412:647.
90. Pasmant E., Sabbagh A., Hanna N., et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 2009, 46:425.
91. Messiaen L., Yao S., Brems H., et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 2009, 302:2111.
92. Evans D.G., Moran A., King A., et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005, 26:93.
93. Evans D.G., Huson S.M., Donnai D., et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992, 29:841.
94. Mautner V.F., Lindenau M., Baser M.E., et al. Skin abnormalities in neurofibromatosis 2. Arch Dermatol 1997, 133:1539.
95. Parry D.M., Eldridge R., Kaiser-Kupfer M.I., et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994, 52:450.
96. Evans D.G., Baser M.E., O'Reilly B., et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005, 19:5.
97. Asthagiri A.R., Parry D.M., Butman J.A., et al. Neurofibromatosis type 2. Lancet 2009, 373:1974.
98. Ruggieri M., Iannetti P., Polizzi A., et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 2005, 36:21.
99. Evans D.G., Birch J.M., Ramsden R.T. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999, 81:496.
100. MacCollin M., Mautner V.F. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 1998, 5:243.
101. Nunes F., MacCollin M. Neurofibromatosis 2 in the pediatric population. J Child Neurol 2003, 18:718.
102. Rouleau G.A., Merel P., Lutchman M., et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993, 363:515.
103. Trofatter J.A., MacCollin M.M., Rutter J.L., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993, 72:791.
104. Evans D.G., Wallace A.J., Wu C.L., et al. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998, 63:727.
105. Evans D.G., Trueman L., Wallace A., et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998, 35:450.
106. Albright F., Butler A.M., Hampton A.O., et al. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females: report of five cases. N Engl J Med 1937, 216:727.
107. Hogeling M., Frieden I.J. Segmental pigmentation disorder. Br J Dermatol 2010, 162:1337.
108. McCune D.J. Osteitis fibrosa cystica; the case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 1936, 52:743.
109. Lumbroso S., Paris F., Sultan C. McCune-Albright syndrome: molecular genetics. J Pediatr Endocrinol Metab 2002, 15(Suppl 3):875.
110. Ringel M.D., Schwindinger W.F., Levine M.A. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996, 75:171.
111. Albers N., Jorgens S., Deiss D., et al. McCune-Albright syndrome-the German experience. J Pediatr Endocrinol Metab 2002, 15(Suppl 3):897.
112. de Sanctis C., Lala R., Matarazzo P., et al. McCune-Albright syndrome: a longitudinal clinical study of 32 patients. J Pediatr Endocrinol Metab 1999, 12:817.
113. Lumbroso S., Paris F., Sultan C. Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome-a European Collaborative Study. J Clin Endocrinol Metab 2004, 89:2107.
114. Diaz A., Danon M., Crawford J. McCune-Albright syndrome and disorders due to activating mutations of GNAS1. J Pediatr Endocrinol Metab 2007, 20:853.
115. Lala R., Matarazzo P., Andreo M., et al. Impact of endocrine hyperfunction and phosphate wasting on bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002, 15(Suppl 3):913.
116. Shenker A., Weinstein L.S., Moran A., et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993, 123:509.
117. Benedict P.H., Szabo G., Fitzpatrick T.B., et al. Melanotic macules in Albright's syndrome and in neurofibromatosis. JAMA 1968, 205:618.
118. Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 1986, 29:321.
119. Bowerman J.E. Polyostotic fibrous dysplasia with oral melanotic pigmentation. Br J Oral Surg 1969, 6:188.
120. Gorlin R.J., Chaudhry A.P. Oral melanotic pigmentation in polyostotic fibrous dysplasia, Albright's syndrome. Oral Surg Oral Med Oral Pathol 1957, 10:857.
121. Schwindinger W.F., Francomano C.A., Levine M.A. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A 1992, 89:5152.
122. Weinstein L.S., Shenker A., Gejman P.V., et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991, 325:1688.
123. Donovan S., Shannon K.M., Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002, 1602:23.
124. Weinstein L.S. G(s)alpha mutations in fibrous dysplasia and McCune-Albright syndrome. J Bone Miner Res 2006, 21(Suppl 2):P120.
125. Kim I.S., Kim E.R., Nam H.J., et al. Activating mutation of GS alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. Horm Res 1999, 52:235.
126. Wimmer K., Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?. Hum Genet 2008, 124:105.
127. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003, 348:919.
128. De Vos M., Hayward B.E., Charlton R., et al. PMS2 mutations in childhood cancer. J Natl Cancer Inst 2006, 98:358.
129. Kruger S., Kinzel M., Walldorf C., et al. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. Eur J Hum Genet 2008, 16:62.
130. Scott R.H., Mansour S., Pritchard-Jones K., et al. Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 2007, 4:130.
131. Tan T.Y., Orme L.M., Lynch E., et al. Biallelic PMS2 mutations and a distinctive childhood cancer syndrome. J Pediatr Hematol Oncol 2008, 30:254.
132. Gallinger S., Aronson M., Shayan K., et al. Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 2004, 126:576.
133. Hegde M.R., Chong B., Blazo M.E., et al. A homozygous mutation in MSH6 causes Turcot syndrome. Clin Cancer Res 2005, 11:4689.
134. Ostergaard J.R., Sunde L., Okkels H. Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6. Am J Med Genet A 2005, 139A:96.
135. Vilkki S., Tsao J.L., Loukola A., et al. Extensive somatic microsatellite mutations in normal human tissue. Cancer Res 2001, 61:4541.
136. Raevaara T.E., Gerdes A.M., Lonnqvist K.E., et al. HNPCC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1. Genes Chromosomes Cancer 2004, 40:261.
137. Ricciardone M.D., Ozcelik T., Cevher B., et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 1999, 59:290.
138. Wang Q., Lasset C., Desseigne F., et al. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res 1999, 59:294.
139. Menko F.H., Kaspers G.L., Meijer G.A., et al. A homozygous MSH6 mutation in a child with café-au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer 2004, 3:123.
140. Trimbath J.D., Petersen G.M., Erdman S.H., et al. Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC?. Fam Cancer 2001, 1:101.
141. Scott R.H., Homfray T., Huxter N.L., et al. Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations. J Med Genet 2007, 44:e83.
142. Wang Q., Montmain G., Ruano E., et al. Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum Genet 2003, 112:117.
143. Fagan K., Suthers G.K., Hardacre G. Ring chromosome 11 and café-au-lait spots. Am J Med Genet 1988, 30:911.
144. Morava E., Bartsch O., Czako M., et al. A girl with cutaneous hyperpigmentation, café au lait spots and ring chromosome 15 without significant deletion. Genet Couns 2003, 14:337.
145. Park J.P., Graham J.M., Andrews P.A., et al. Ring chromosome 12. Am J Med Genet 1988, 29:437.
146. Shashi V., White J.R., Pettenati M.J., et al. Ring chromosome 17: phenotype variation by deletion size. Clin Genet 2003, 64:361.
147. Surace C., Piazzolla S., Sirleto P., et al. Mild ring 17 syndrome shares common phenotypic features irrespective of the chromosomal breakpoints location. Clin Genet 2009, 76:256.
148. Vollenweider Roten S., Masouye I., Delozier-Blanchet C.D., et al. Cutaneous findings in ring chromosome 7 syndrome. Dermatology 1993, 186:84.
149. Wahlstrom J., Bjarnason R., Rosdahl I., et al. Boy with a ring 7 chromosome: a case report with special reference to dermatological findings. Acta Paediatr 1996, 85:1256.
150. Zen P.R., Pinto L.L., Graziadio C., et al. Association of microcephaly and café-au-lait spots in a patient with ring chromosome 12 syndrome. Clin Dysmorphol 2005, 14:141.
151. Alora M.B., Arndt K.A. Treatment of a café-au-lait macule with the erbium:YAG laser. J Am Acad Dermatol 2001, 45:566.
152. Alster T.S. Complete elimination of large café-au-lait birthmarks by the 510-nm pulsed dye laser. Plast Reconstr Surg 1995, 96:1660.
153. Alster T.S., Williams C.M. Café-au-lait macule in type V skin: successful treatment with a 510 nm pulsed dye laser. J Am Acad Dermatol 1995, 33:1042.
154. Carpo B.G., Grevelink J.M., Grevelink S.V. Laser treatment of pigmented lesions in children. Semin Cutan Med Surg 1999, 18:233.
155. Idorn L.W., Haedersdal M. Paradoxical postoperative hyperpigmentation from Q-switched YAG laser treatment of pigmented lesions in children with fair skin types. J Eur Acad Dermatol Venereol 2009, 23:856.
156. Kim J.S., Kim M.J., Cho S.B. Treatment of segmental café-au-lait macules using 1064-nm Q-switched Nd:YAG laser with low pulse energy. Clin Exp Dermatol 2009, 34:e223.
157. Nelson J.S., Applebaum J. Treatment of superficial cutaneous pigmented lesions by melanin-specific selective photothermolysis using the Q-switched ruby laser. Ann Plast Surg 1992, 29:231.
158. Shimbashi T., Kamide R., Hashimoto T. Long-term follow-up in treatment of solar lentigo and café-au-lait macules with Q-switched ruby laser. Aesthetic Plast Surg 1997, 21:445.
159. Somyos K., Boonchu K., Somsak K., et al. Copper vapour laser treatment of café-au-lait macules. Br J Dermatol 1996, 135:964.
160. Tse Y., Levine V.J., McClain S.A., et al. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser. A comparative study. J Dermatol Surg Oncol 1994, 20:795.